

Ernst Schering Research Foundation Workshop 57  
The Histone Code and Beyond

Ernst Schering Research Foundation  
Workshop 57

# The Histone Code and Beyond

New Approaches to Cancer Therapy

S.L. Berger, O. Nakanishi, B. Haendler  
Editors

With 36 Figures

 Springer

Series Editors: G. Stock and M. Lessl

---

Library of Congress Control Number: 2005932740

ISSN 0947-6075

ISBN-10 3-540-27857-5 Springer Berlin Heidelberg New York

ISBN-13 978-3-540-27857-3 Springer Berlin Heidelberg New York

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer-Verlag. Violations are liable for prosecution under the German Copyright Law.

Springer is a part of Springer Science+Business Media  
springeronline.com

© Springer-Verlag Berlin Heidelberg 2006  
Printed in Germany

The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. Product liability: The publisher cannot guarantee the accuracy any information about dosage and application contained in this book. In every individual case the user must check such information by consulting the relevant literature.

Editor: Dr. Ute Heilmann, Heidelberg  
Desk Editor: Wilma McHugh, Heidelberg  
Production Editor: Monika Riepl, Leipzig  
Cover design: design & production, Heidelberg  
Typesetting and production: LE-TeX Jelonek, Schmidt & Vöckler GbR, Leipzig  
21/3150/YL – 5 4 3 2 1 0 Printed on acid-free paper

## ***Preface***

---

In recent years, it has been recognized that epigenetic marks play an essential role in the control of gene expression by modulating the access of regulatory factors to chromatin. Evidence is now accumulating that deregulation of these control mechanisms is linked to cancer initiation and progression.



In the chromatin, DNA is packaged around histone proteins and generally in the default state of repression. DNA regions that are to be transcribed are temporarily made accessible by decondensing the structure. For the uncoiling of chromatin, histones can be post-translationally modified at many positions, mainly located in their N-terminal tails. A range of histone modifications including phosphorylation, acetylation, methylation and ubiquitylation, all carried out by different families of specific enzymes, have been identified in recent years.

Another epigenetic event is DNA methylation, which often takes place on cytosine residues in CpG islands found in gene promoter regions. Aberration in DNA methylation is now recognized as a fundamental aspect of human cancer, each tumor type having its own DNA methylation pattern.

Besides histones, post-translational modifications affect and regulate a variety of additional proteins with important functions in signal transduction and gene transcription. Ubiquitylation, sumoylation and neddylation represent three related processes that may dramatically affect the function of targeted proteins, for instance by regulating their stability, subcellular localization or interactions with other proteins.

All these exciting developments in the area of chromatin research prompted us to organize a meeting to discuss the most recent breakthroughs made in this fast-moving field, with a focus on aspects relevant to cancer research. The following topics were selected for the workshop: chromatin dynamics, histone and DNA methylation, histone code and covalent modifications of nonhistone proteins.

We were pleased to be able to bring together internationally highly recognized experts who study this field using a variety of biochemical, genetic and structural approaches. We are grateful to all of them for their willingness to participate and for their excellent contributions.

We hope that the proceedings of this workshop will promote a better understanding of the mechanisms responsible for epigenetic control of gene expression and help to identify novel targets for tumor treatment in the near future.

*Shelley L. Berger*  
*Osamu Nakanishi*  
*Bernard Haendler*

# Contents

---

1	The Role of Histone Modifications in Epigenetic Transitions During Normal and Perturbed Development <i>S. Kubicek, G. Schotta, M. Lachner, R. Sengupta, A. Kohlmaier, L. Perez-Burgos, Y. Linderson, J.H.A. Martens, R.J. O'Sullivan, B.D. Fodor, M. Yonezawa, A.H.F.M. Peters, T. Jenuwein</i> . . . . .	1
2	Nucleosome Structure and Function <i>J.V. Chodaparambil, R.S. Edayathumangalam, Y. Bao, Y.-J. Park, K. Luger</i> . . . . .	29
3	The Role of Snf2-Related Proteins in Cancer <i>T. Owen-Hughes</i> . . . . .	47
4	Imitation Switch Complexes <i>J. Mellor</i> . . . . .	61
5	How Is Epigenetic Information on Chromatin Inherited After DNA Replication? <i>Y. Nakatani, H. Tagami, E. Shestakova</i> . . . . .	89
6	Polycomb Silencing Mechanisms and Genomic Programming <i>V. Pirrotta</i> . . . . .	97

7	CpG Island Methylation and Histone Modifications: Biology and Clinical Significance <i>M. Esteller</i> . . . . .	115
8	Histone Post-Translational Modifications Regulate Transcription and Silent Chromatin in <i>Saccharomyces cerevisiae</i> <i>N.C. Tolga Emre, S.L. Berger</i> . . . . .	127
9	Histone Acetylation-Mediated Chromatin Compaction During Mouse Spermatogenesis <i>J. Govin, C. Lestrat, C. Caron, C. Pivot-Pajot, S. Rousseaux, S. Khochbin</i> . . . . .	155
10	Role of Ubiquitin-Like Proteins in Transcriptional Regulation <i>R.T. Hay</i> . . . . .	173
11	Interplay of the SUMO and MAP Kinase Pathways <i>S.-H. Yang, A.D. Sharrocks</i> . . . . .	193
	Previous Volumes Published in This Series . . . . .	211

## ***List of Editors and Contributors***

---

### **Editors**

*Berger, S.L.*

The Wistar Institute, Gene Expression and Regulation Program  
3601 Spruce Street, Room 201, PA 19104 Philadelphia, USA  
(e-mail: berger@wistar.org)

*Nakanishi, O.*

CRBA Oncology, Nihon Schering, Kobe, Japan  
(e-mail: onakanishi@schering.com.jp)

*Haendler, B.*

CRBA Oncology, Schering AG,  
Müllerstr. 178, 13342 Berlin, Germany  
(e-mail: bernard.haendler@schering.de)

### **Contributors**

*Bao, Y.*

Department of Biochemistry and Molecular Biology,  
Colorado State University,  
Fort Collins, CO 80523-1870, USA

*Caron, C.*

Laboratoire de Biologie Moléculaire et Cellulaire de la Différenciation,  
INSERM U 309, Equipe Chromatine et Expression des Gènes,  
Institut Albert Bonniot, Faculté de Médecine, Domaine de la Merci,  
38706 La Tronche Cedex, France



*Chodaparambil, J.Y.*

Department of Biochemistry and Molecular Biology,  
Colorado State University,  
Fort Collins, CO 80523-1870, USA

*Edayathumangalam, R.S.*

Department of Biochemistry and Molecular Biology,  
Colorado State University,  
Fort Collins, CO 80523-1870, USA

*Emre N.C.T.*

Gene Expression & Regulation Program, The Wistar Institute,  
3601 Spruce St. Rm 201, Philadelphia, PA 19104, USA

*Esteller, M.*

Spanish National Cancer Center (CNIO) Epigenetics Laboratory,  
Molecular Pathology Programme,  
Melchor Fernandez Almagro 3, 28029 Madrid, Spain  
(e-mail: mesteller@cnio.es)

*Fodor, B.D.*

Research Institute of Molecular Pathology (IMP), The Vienna Biocenter,  
Dr. Bohrgasse 7, 1030 Vienna, Austria  
(e-mail: fodor@imp.univie.ac.at)

*Govin, J.*

Laboratoire de Biologie Moléculaire et Cellulaire de la Différenciation,  
INSERM U 309, Equipe Chromatine et Expression des Gènes,  
Institut Albert Bonniot, Faculté de Médecine, Domaine de la Merci,  
38706 La Tronche Cedex, France

*Hay, R.T.*

Centre for Biomolecular Sciences, School of Biology,  
University of St. Andrews, Building North Haugh,  
St. Andrews, KY 169ST Fife, Scotland, UK  
(e-mail: rth@st-and.ac.uk)

*Jenuwein, Th.*

Research Institute of Molecular Pathology (IMP), The Vienna Biocenter,  
Dr. Bohrgasse 7, 1030 Vienna, Austria  
(e-mail: jenuwein@imp.univie.ac.at)

*Khochbin, S.*

Laboratoire de Biologie Moléculaire et Cellulaire de la Différenciation,  
INSERM U 309, Equipe Chromatine et Expression des Gènes,  
Institut Albert Bonniot, Faculté de Médecine, Domaine de la Merci,  
38706 La Tronche Cedex, France  
(e-mail: khochbin@ujf-grenoble.fr)

*Kohlmaier, A.*

Research Institute of Molecular Pathology (IMP), The Vienna Biocenter,  
Dr. Bohrgasse 7, 1030 Vienna, Austria  
(e-mail: kohlmaier@imp.univie.ac.at)

*Kubicek, St.*

Research Institute of Molecular Pathology (IMP), The Vienna Biocenter,  
Dr. Bohrgasse 7, 1030 Vienna, Austria  
(e-mail: kubicek@imp.univie.ac.at)

*Lachner, M.*

The Rockefeller University,  
1230 York Avenue, New York, NY 10021, USA  
(e-mail: mlachner@mail.rockefeller.edu)

*Lestrat, C.*

Laboratoire de Biologie Moléculaire et Cellulaire de la Différenciation,  
INSERM U 309, Equipe Chromatine et Expression des Gènes,  
Institut Albert Bonniot, Faculté de Médecine, Domaine de la Merci,  
38706 La Tronche Cedex, France

*Linderson, Y.*

Research Institute of Molecular Pathology (IMP), The Vienna Biocenter,  
Dr. Bohrgasse 7, 1030 Vienna, Austria  
(e-mail: linderson@imp.univie.ac.at)

*Luger, K.*

Department of Biochemistry and Molecular Biology,  
Colorado State University,  
Fort Collins, CO 80523-1870, USA  
(e-mail: kluger@lamar.colostate.edu)

*Martens, J.H.A.*

Research Institute of Molecular Pathology (IMP), The Vienna Biocenter,  
Dr. Bohrgasse 7, 1030 Vienna, Austria  
(e-mail: martens@imp.univie.ac.at)

*Mellor, J.*

Department of Biochemistry,  
Oxford, South Parks Road, OX1 3 QU Oxford, UK  
(e-mail: jane.mellor@bioch.ox.ac.uk)

*Nakatani, Y.*

Dana-Farber Cancer Institute and Harvard Medical School,  
MA 02115 Boston, USA  
(e-mail: yoshihiro\_nakatani@dfci.harvard.edu)

*O'Sullivan, R.J.*

Research Institute of Molecular Pathology (IMP), The Vienna Biocenter,  
Dr. Bohrgasse 7, 1030 Vienna, Austria  
(e-mail: osullivan@imp.univie.ac.at)

*Owen-Hughes, T.*

Division of Gene Regulation and Expression, School of Life Sciences,  
University of Dundee,  
DD1 5EH, Dundee, Scotland UK  
(e-mail: t.a.owenhughes@dundee.ac.uk)

*Park, Y.-J.*

Department of Biochemistry and Molecular Biology,  
Colorado State University,  
Fort Collins, CO 80523-1870, USA

*Perez-Burgos, L.*

Research Institute of Molecular Pathology (IMP), The Vienna Biocenter,  
Dr. Bohrgasse 7, 1030 Vienna, Austria  
(e-mail: perez@imp.univie.ac.at)

*Peters, A.H.F.M.*

Friedrich Miescher Institute for Biomedical Research (FMI)  
Novartis Research Foundation,  
Maulbeerstrasse 66, CH-4058 Basel, Switzerland  
(e-mail: Antoine.Peters@fmi.ch)

*Pirrotta, V.*

Department of Molecular Biology and Biochemistry, Rutgers University,  
604 Allison Road, Piscataway NJ 08854, USA  
(e-mail: pirrotta@biology.rutgers.edu)

*Pivot-Pajot, Ch.*

Laboratoire de Biologie Moléculaire et Cellulaire de la Différenciation,  
INSERM U 309, Equipe Chromatine et Expression des Gènes,  
Institut Albert Bonniot, Faculté de Médecine, Domaine de la Merci,  
38706 La Tronche Cedex, France

*Rousseaux, S.*

Laboratoire de Biologie Moléculaire et Cellulaire de la Différenciation,  
INSERM U 309, Equipe Chromatine et Expression des Gènes,  
Institut Albert Bonniot, Faculté de Médecine, Domaine de la Merci,  
38706 La Tronche Cedex, France

*Schotta, G.*

Research Institute of Molecular Pathology (IMP), The Vienna Biocenter,  
Dr. Bohrgasse 7, 1030 Vienna, Austria  
(e-mail: schotta@imp.univie.ac.at)

*Sengupta, R.*

Research Institute of Molecular Pathology (IMP), The Vienna Biocenter,  
Dr. Bohrgasse 7, 1030 Vienna, Austria  
(e-mail: sengupta@imp.univie.ac.at)

*Sharrocks, A.*

Faculty of Life Sciences, University of Manchester,  
Michael Smith Building,  
Oxford Road, Room A2028, M13 9PT Manchester, GB  
(e-mail: a.d.sharrocks@manchester.ac.uk)

*Shestakova, E.*

Dana-Farber Cancer Institute and Harvard Medical School,  
MA 02115 Boston, USA

*Tagami, H.*

Division of Biological Science, Graduate School of Science,  
Nagoya University, Chikusa, Nagoya, Aichi 464-8602, Japan

*Yang, S.-H.*

Faculty of Life Sciences, University of Manchester,  
Michael Smith Building,  
Oxford Road, Manchester, M13 9PT, UK

*Yonezawa, M.*

Research Institute of Molecular Pathology (IMP), The Vienna Biocenter,  
Dr. Bohrgasse 7, 1030 Vienna, Austria  
(e-mail: yonezawa@imp.univie.ac.at)

# ***1 The Role of Histone Modifications in Epigenetic Transitions During Normal and Perturbed Development***

---

S. Kubicek, G. Schotta, M. Lachner, R. Sengupta, A. Kohlmaier,  
L. Perez-Burgos, Y. Linderson, J.H.A. Martens, R.J. O’Sullivan,  
B.D. Fodor, M. Yonezawa, A.H.F.M. Peters, T. Jenuwein

1.1	The Distinction Between Genome and Epigenomes . . . . .	2
1.2	Activating Histone Modifications . . . . .	5
1.3	Repressive Histone Modifications . . . . .	8
1.4	Reprogramming of Epigenetic Modifications . . . . .	10
1.5	Persistence of Soma-Specific Epigenetic Marks in Cloned Embryos	12
1.6	Epigenetic Transitions During Tumorigenesis . . . . .	15
1.7	From Basic to Applied Research . . . . .	17
	References . . . . .	21

**Abstract.** Epigenetic mechanisms control eukaryotic development beyond DNA-stored information. DNA methylation, histone modifications and variants, nucleosome remodeling and noncoding RNAs all contribute to the dynamic make-up of chromatin under distinct developmental options. In particular, the great diversity of covalent histone tail modifications has been proposed to be ideally suited for imparting epigenetic information. While most of the histone tail modifications represent transient marks at transcriptionally permissive chromatin, some modifications appear more robust at silent chromatin regions, where they index repressive epigenetic states with functions also outside transcriptional

regulation. Under-representation of repressive histone marks could be indicative of epigenetic plasticity in stem, young and tumor cells, while committed and senescent (old) cells often display increased levels of these more stable modifications. Here, we discuss profiles of normal and aberrant histone lysine methylation patterns, as they occur during the transition of an embryonic to a differentiated cell or in controlled self-renewal vs pro-neoplastic or metastatic conditions. Elucidating these histone modification patterns promises to have important implications for novel advances in stem cell research, nuclear reprogramming and cancer, and may offer novel targets for the combat of tumor cells, potentially leading to new diagnostic and therapeutic avenues in human biology and disease.

## 1.1 The Distinction Between Genome and Epigenomes


The DNA double helix is the prime macromolecule to store and propagate genetic information. The key genetic principle is mutation of one or many of the four nucleotides, resulting in a change in the DNA sequence that can ultimately define a new species barrier. The genome of the unicellular eukaryote *Saccharomyces cerevisiae* consists of around 6,000 genes (Goffeau et al. 1996), a number sufficient for controlling basic cellular processes, such as metabolism, cell division, and DNA damage repair. Mammals have five times as many genes (Lander et al. 2001; Waterston et al. 2002), and most of these additional genes can be associated with specialized functions to determine cell type identities and lineage commitment. This results in the phenotypical discrimination of more than 200 cell types. How can these distinct cell types be defined and stably propagated from a common genome?

In eukaryotes, the DNA molecule is not naked, but is organized in chromatin – the dynamic template of the genetic information. The basic repeating unit of chromatin is the nucleosome, consisting of 147 bp of DNA wrapped around an octamer of the core histones H2A, H2B, H3, and H4 (Luger et al. 1997). One of the key epigenetic principles for altering chromatin states are covalent modifications, both of the DNA (methylation) and of the flexible histone N-termini (histone “tails”). An epigenome can thus be defined by the sum of biochemical modifications of the chromatin template. Epigenomes will greatly differ between distinct cell types and among resting vs proliferative cells, and it has

been suggested that histone modifications could reflect a histone code that may index diverse developmental or proliferative options (Strahl and Allis 2000; Turner 2000; Jenuwein and Allis 2001). Currently, more than 30 amino acid positions have been described in the N-termini of the four core histones to be subject to distinct post-translational modifications. Although this large number may be counter-intuitive for a histone code and rather reflect biochemical affinities for chromatin-associated factors (Schreiber and Bernstein 2002), several histone modifications, and in particular distinct combinations of selective histone marks, appear to be of predictive value (see Sects. 1.2 and 1.3).

In addition to DNA methylation, histone modifications and variants (Sarma and Reinberg 2005), nucleosome remodeling factors (Narlikar et al. 2002) and noncoding RNAs (Lippman and Martienssen 2004) all cooperate to organize chromatin into accessible (euchromatic) or inaccessible (heterochromatic) subdomains. These epigenetic mechanisms considerably extend the information potential of the genetic code and are important for the differential usage of gene function during cell type specification. Thus, one genome can generate many epigenomes (Fig. 1), as the fertilized egg progresses through development and translates its information into a multitude of cell fates. As a general pattern, activating epigenetic mechanisms appear to prevail in stem, young, and tumor cells, since these cells would allow access to the nearly full gene comple-


---



**Fig. 1.** Genome vs epigenomes. The figure illustrates the distinction between genome (DNA sequence) and epigenome (the collective modification pattern of chromatin). Diverse mechanisms including DNA methylation, histone modifications and variants, chromatin-remodeling activities, and noncoding RNAs contribute to the generation of distinct epigenomes, as the fertilized egg progresses during development. The various epigenetic modifications are indicated as histone acetylation (*blue flag*), histone lysine methylation (*green hexagons* for active and *red or blue hexagons* for repressive marks), histone arginine methylation (*orange hexagon*) DNA methylation (*small brown hexagons*), histone variants (*yellow nucleosome*) and remodeling complexes (e.g., ISWI). Euchromatin allows transcription factors (TF) to access the underlying DNA sequence, while repressive modifications that may be induced by small noncoding RNAs could lead to the further compaction of heterochromatic domains



ment. A transcriptionally permissive state would therefore be indicative of cellular plasticity and pluripotency. By contrast, repressive mechanisms accumulate in committed and old cells and stabilize developmental options by restricting expression of lineage-inappropriate genes. Both activating and repressive epigenetic mechanisms are important for transcriptional control, but also play major roles in overall chromatin




organization to partition eukaryotic chromosomes into centromeric and telomeric domains, to index recombination sites and to respond to DNA damage repair. The implications of epigenetic mechanisms for human biology and disease, including genome stability, cancer, stem cells, and aging are far-reaching.

## 1.2 Activating Histone Modifications

Histone modifications include acetylation, phosphorylation, methylation (of arginines and lysines), ubiquitination, sumoylation and ADP-ribosylation (van Holde 1988). These modifications are predominantly found in the flexible N-termini of the small (102–135 amino acids) histone proteins. One nucleosome contains two copies of the four core histones, and approximately 30 amino acids (the histone tails) of each histone molecule protrude from one nucleosome. If only these amino acids are considered, this would result in the potential of  $2 \times 4 \times 30$  positions conferring epigenetic information per nucleosome. That each amino acid is important is suggested by the extremely high evolutionary conservation of the histone sequences. However, histone modifications do not appear to occur in isolation, but rather in a combinatorial manner as proposed for modification cassettes (Fischle et al. 2003) and trans-histone pathways (Briggs et al. 2002). Intriguingly, almost all of the known histone modifications can either have an activating or a repressive function, dependent on which amino acid position(s) in the histone N-termini are modified (see Sect. 1.3). Both synergistic and antagonistic pathways have been described (Berger 2002) that can progressively induce combinations of active marks while simultaneously counteracting repressive modifications. It is, however, not known how many distinct combinations for modifications of the various N-terminal histone positions indeed exist in any given nucleosome, although some of the major sites can be modified at 60%–80% in bulk histone preparations (Peters et al. 2003; Rice et al. 2003). In addition to the N-termini, modifications in the globular histone fold domains have recently been shown to also impact chromatin structure and assembly, thereby influencing gene expression and DNA damage repair (van Leeuwen et al. 2002; Ng et al. 2002; Freitas et al. 2003; Xu et al. 2005, Ye et al. 2005).

Activating histone tail modifications have been shown to comprise general H3 and H4 acetylation, H3S10 phosphorylation, arginine methylation at H3R17 and lysine methylation at H3K4 and H3K36 positions (Lachner et al. 2003), although there are many others. Histone acetyltransferases (HATs), kinases, protein arginine methyltransferases (PRMTs), and histone methyltransferases (HMTases) are the enzymes that confer these modifications (Fig. 2). The various activating histone modifications are induced by these enzymatic activities, which can either be associated in multi-protein complexes or are recruited to the chro-



**Fig. 2.** Activating histone modifications and associated enzymes. Activating histone modifications comprise lysine acetylation (*blue flag*), serine and threonine phosphorylation (*yellow circle*), arginine methylation (*orange hexagon*), and lysine methylation at positions H3K4, H3K36, and H3K79 (*green hexagons*). Lysine acetylation is recognized by bromo-domain factors, while lysine methylation can recruit chromo-domain proteins. Specific binders for histone phosphorylation and arginine methylation are currently not known. Activating modifications are induced by histone acetyltransferases (*HATs*), kinases, protein arginine methyltransferases (*PRMTs*), and histone lysine methyltransferases (*HMTases*). Most of these marks are transient and can be actively removed by histone deacetylases (*HDACs*), protein phosphatases (*PPTases*), deiminases and amine oxidases

matin template in a sequential order by transcription factors, nucleosome remodelers or the RNA-PolIII machinery (Sarma and Reinberg 2005). Histone modifications can result in *cis*-effects, which alter electrostatic interactions of the DNA polymer with nucleosomes. For example, both acetylation and phosphorylation will reduce the net positive charge of the basic histone molecules, thereby increasing overall accessibility of nucleosomal DNA. Alternatively, histone modifications can generate affinities for chromatin-associated factors, which then mediate transitions of the chromatin template by *trans*-mechanisms. This has been shown for histone acetylation in providing a recruiting signal for positively acting bromo domain factors (Dhalluin et al. 1999; Jacobson et al. 2000) and for histone lysine methylation, which represents binding sites for chromo domain (Daniel et al. 2005) or WDR5 proteins (Wysocka et al. 2005). Currently, no protein modules that selectively recognize histone arginine methylation or H3S10 phosphorylation are known.

Most activating modifications are transient and can be actively removed, for example by histone deacetylases (HDACs), protein phosphatases (PPTases) and peptidyl arginine deiminases (PADs). PADs convert unmodified or monomethylated arginine to citrulline, thereby inducing an alteration in amino acid composition (Wang et al. 2004; Cuthbert et al. 2004). The function and stability of citrulline in histones or nucleosomes is currently not clear. In contrast to arginine methylation, lysine methylation is considered a chemically very stable modification, as the amino-methyl bond cannot be cleaved directly. However, recently a lysine specific “demethylase” (LSD1) was described as an amine oxidase that is able to remove H3K4 methylation (Shi et al. 2004). The enzyme acts by oxidative destabilization of the amino-methyl bond, resulting in unmodified lysine and formaldehyde. LSD1 was shown to be selective for the activating H3K4 methylation mark and can only destabilize mono- and di-, but not trimethylation. This demethylase is part of a large repressive protein complex that also contains HDACs and other enzymes (Shi et al. 2004). Similar to the collaboration of activating enzymes (e.g., HATs and PRMTs) in inducing combinations of positive histone modifications, there is synergy between antagonizing enzymes (e.g., HDACs and PADs) in removing or counteracting these activating marks.


### 1.3 Repressive Histone Modifications

In addition to DNA methylation (Jaenisch and Bird 2003), many of the known histone modifications can also exert a repressive function on the chromatin template. In particular, histone lysine methylation has emerged as a central epigenetic modification that can index silenced chromatin regions. There are five well-characterized and prominently methylated lysine positions in the histone H3 and H4 N-termini, although there are additional methylation sites also in the globular domains (van Leeuwen et al. 2002; Ng et al. 2002) and in the linker histone H1 (Kuzmichev et al. 2004). Whereas H3K4 and H3K36 methylation are activating marks (see Sect. 1.2), histone H3 lysine 9 (H3K9), lysine 27 (H3K27) and histone H4 lysine 20 (H4K20) methylation represent OFF marks that are mainly involved in the organization of repressive chromatin structures (Peters et al. 2003; Schotta et al. 2004). All of the five major histone lysine methylation sites can exist in three distinct states: mono-, di- and trimethylation (Fig. 3).

The existence of three lysine methylation states provides an additional layer of regulatory control, since mono-, di- and trimethylation may serve diverse biological functions. For example, there are more than 50 SET-domain HMTases in mammals (Schneider et al. 2002; Schotta et al. 2004), which differ in their potential to induce mono- vs di- vs trimethylation. Dependent on a distributive or processive activity (Zhang et al. 2003), some of these enzymes can only establish monomethylation (e.g., PR-SET7) (Nishioka et al. 2002; Xiao et al. 2005), while others convert an unmodified substrate to several methylation states (e.g., EZH2) (Kuzmichev et al. 2004) or are specialized to induce the fully methylated end state of trimethylation (e.g., Suv39h) (Peters et al. 2003). Methylation at distinct histone lysine positions generates selective binding sites for chromatin-associated factors containing a chromo domain, as was first demonstrated for HP1 to interact with H3K9me3 and for Polycomb to display affinity toward H3K27me3 (Daniel et al. 2005; Ringrose and Paro 2004).

Recently, the chromo-domain superfamily of “royal proteins” (Maurer-Stroh et al. 2003) has been shown to comprise additional methyl-lysine binders, such as tudor domain (Sanders et al. 2004) or malignant brain tumor (MBT) (W. Fischle and C.D. Allis, personal communica-

tion) proteins. Interestingly, some of these factors not only discriminate between distinct methyl-lysine positions in the histone N-termini, but also are selective to recognize a mono-, di- or trimethyl state (Fig. 3). Currently, no enzymes removing repressive histone lysine trimethyl marks are known. This is consistent with the apparent stability of H3K9, H3K27, and H4K20 trimethylation, which can persist through mitosis and over many cell generations (Peters et al. 2003; Schotta et al. 2004). This robustness has been used to suggest that repressive histone lysine



**Fig. 3.** Repressive histone lysine methylation states. Lysine methylation at H3K9, H3K27, and H4K20 positions are among the best characterized repressive histone modifications. The  $\epsilon$ -amino group of lysines can be modified by mono-, di-, and trimethylation. Originally, chromo domain proteins were the first factors identified to bind methylated lysines in the histone N-termini. This group of methyl-lysine binders has recently been extended by members of the royal family, such as malignant brain tumor (*MBT*) and tudor domains. Histone lysine methylation is induced by HMTases that can differ in their potential to generate mono-, di-, or trimethylation. Whereas mono- and dimethyl states can be destabilized by amine oxidases, more potent mechanisms (e.g., radical attack and hydroxylation) are required to remove a trimethyl state. Currently, no enzymes are known that would destabilize repressive histone lysine trimethyl marks

trimethyl states may be particularly suited to impart epigenetic memory to a differentiating cell. However, in analogy to LSD1 described in Sect. 1.2, it is formally possible for an amine oxidase to destabilize repressive histone lysine mono- or dimethyl states. Such enzymes may most likely be present in diverse protein complexes with other activating enzymes, such as HATs or PRMTs and HMTases (e.g., trx and MLL) that can induce positive acetylation and methylation marks. Indeed, an LSD1-like activity to counteract repressive H3K9me2 has recently been described for the transcriptional activation of genes that respond to certain hormones (Metzger et al. 2005). Here, LSD1 can associate with the androgen receptor in a complex formation, which apparently converts the substrate specificity of LSD1 at target promoters to act on H3K9me2 rather than on H3K4me2. Even when complexed with the androgen receptor (which may induce an altered substrate presentation of the H3 N-terminus), LSD1 cannot convert H3K9me3 (Metzger et al. 2005), and the enzymatic reaction of amine oxidation is incompatible to destabilize lysine trimethylation. Alternative mechanisms have been proposed, and attack of the amino-methyl bond by oxygen radicals involving hydroxylation could represent a plausible pathway. In particular, conserved jumonji (jmjC) domain enzymes, which require  $\text{Fe}^{2+}$  and oxoglutarate as co-factors, have been suggested as potential hydroxylases that could remove histone lysine trimethylation (Trewick et al. 2005). However, since repressive histone lysine trimethyl states appear very stable, such hydroxylating enzymes may be of very low abundance or could be extremely tightly regulated during early development and in lineage commitment. There are ongoing experiments in many laboratories to identify these putative methyl-lysine hydroxylases, which promise to be novel candidates for exploratory research, since their neutralization by small molecule inhibitors would increase chromosome stability and potentially counteract plasticity of gene expression and pro-neoplastic dysfunction.

#### 1.4 Reprogramming of Epigenetic Modifications

Alterations in DNA methylation patterns (Bird 2002), misregulated chromatin remodeling (Klochendler-Yeivin et al. 2002; Narlikar et al. 2002), and changes in histone modifications (Schneider et al. 2002) have been linked with perturbed development, tumorigenesis (Jones and Baylin